"The US Food and Drug Administration (FDA) has approved an amphetamine extended-release orally disintegrating tablet (Adzenys XR-ODT) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older. A"...
The following are adverse reactions in decreasing order of severity within each category that have been reported:
Elevation of blood pressure, tachycardia and palpitation. Fatal cardiorespiratory arrest has been reported, mostly in the context of abuse/misuse.
Central Nervous System
Psychotic episodes have been rarely reported at recommended doses. Dizziness, dysphoria, overstimulation, euphoria, insomnia, tremor, restlessness and headache. Exacerbation of motor and phonic tics and Tourette’s syndrome.
Diarrhea, constipation, dryness of mouth, unpleasant taste and other gastrointestinal disturbances.
Suppression of growth has been reported with the long-term use of stimulants in children (see WARNINGS).
To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Read the Desoxyn (methamphetamine hydrochloride) Side Effects Center for a complete guide to possible side effects
Methamphetamine may decrease the hypotensive effect of guanethidine.
DESOXYN should not be used concurrently with monoamine oxidase inhibitors (see CONTRAINDICATIONS).
Concurrent administration of tricyclic antidepressants and indirect-acting sympathomimetic amines such as the amphetamines, should be closely supervised and dosage carefully adjusted.
Phenothiazines are reported in the literature to antagonize the CNS stimulant action of the amphetamines.
Drug Abuse And Dependence
Controlled Substance: DESOXYN tablets are subject to control under DEA schedule II.
Methamphetamine has been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with methamphetamine include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis often clinically indistinguishable from schizophrenia. Abuse and/or misuse of methamphetamine have resulted in death. Fatal cardiorespiratory arrest has been reported in the context of abuse and/or misuse of methamphetamine.
Read the Desoxyn Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 10/14/2016
Additional Desoxyn Information
Desoxyn - User Reviews
Desoxyn User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.